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provide PE education, however the number of hours is sufficiently greater for
schools with an elective (variable) course in PE. In addition, results pertaining to the
opinions of key educators on the insufficiency of number of hours devoted to
PE-related topics and on enhancing PE education should be noted.
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OBJECTIVES: Early Access Programmes (EAPs) provide the possibility of making
medicines that address an unmet medical need available to patients before regu-
latory approval of the European Medicine Agency. Market Access includes market
development activities and patient access strategy, EAPs can positively impact
both areas. The aim of this review is to consider, compile and describe the main
EAPs available in Europe. METHODS: We conducted a review and performed a
mapping of EAPs systems that exists in Europe. We searched existing literature in
Embase, National Health Systems Website, ISPOR conference websites and Inter-
net. In the countries where information were more scattered we directly contacted
regulatory agencies and clinicians familiar with the local EAP regulations and
practices. RESULTS: We described the practical implications surrounding the reg-
ulatory framework for EAPs, the key stakeholders involved in EAP decision-making
and administration, the timelines for EAPs approval, and the key factors for suc-
cess. Many countries do not have an EAP in place and compassionate use is the only
route to market for unregistered or investigational products. This is the case for
Germany, Belgium, Poland, Austria and Switzerland. The markets where EAP are
more developed and sales are possible are: France, Spain, UK, Italy, Sweden, Den-
mark, Portugal, and Norway. CONCLUSIONS: This project made specific recom-
mendations on the most favourable countries, based on the ease of setting up such
a programme and the potential revenue that could result. At the time, there were
several countries where the legal framework was changing (e.g. Austria) and some
markets where information was simply not available.
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EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY: DIFFERENCES BETWEEN
PHARMACEUTICAL COMPANIES’ CLAIMS AND IQWIG BENEFIT ASSESSMENTS
Ruof J1, Dintsios CM2, Schwartz F3
1Roche Pharma, Grenzach-Wyhlen, Germany, 2German Association of Research-based
Pharmaceutical Companies (vfa), Berlin, Germany, 3Hannover Medical School, Hannover,
Germany
OBJECTIVES: Since January 2011 the new German AMNOG health care reform in-
cludes a mandatory EBA for innovative medicines. At time of launch pharmaceu-
tical companies have to submit a benefit dossier which is subsequently evaluated
by the Institute for Quality and Efficiency in Health Care (IQWiG). Our aim was to
explore differences in companies’ benefit claims and the respective IQWiG
assessments. METHODS: The review includes EBAs that were started in 2011. The
Joint Federal Committee’s (GBA) webpage was used to obtain the respective com-
panies’ benefit claims and IQWiG overall (i.e. aggregated, not on endpoint level)
benefit assessments. The GBA’s official scale is discriminating six levels of addi-
tional benefit versus comparative treatment: 1: major; 2: significant; 3: marginal; 4:
not quantifiable; 5: no benefit; 6: less benefit. IQWiG’s official evidence categories
include: 1: proof; 2: indication; 3: hint. For the purpose of this abstract always the
highest benefit level and evidence category claimed/assessed was taken into
account. RESULTS: Twenty-four EBAs were started in 2011: Tafamidis Meglumin,
Telaprevir, Abirateronacetat, Linagliptin, Pirfenidon, Boceprevir, Bromfenac, Ipili-
mumab, Fampridin, Belimumab, Belatacept, Dexmedetomidin, Cannabis Sativa,
Apixaban, Pitavastatin, Retigabin, Aliskiren/Amlodipin, Collagenase, Eribulin,
Cabazitaxel, Fingolimod, Regadenoson, Ticacrelor, Olmesartan/Amlodipin/Hydro-
chlorthiazid. The companies’ benefit claims/IQWiG benefit assessments included
the benefit level: major in 11/0 EBAs; significant 4/4; marginal 0/3; not quantifiable
1/2; no benefit 1/8; less benefit 0/0. Two Orphan indications were excluded from
this analysis; for five drugs no full dossier submissions and/or IQWiG assessments
were conducted (Bromfenac; Dexmedetomidin; Pitavastatin; Regadenoson; Olm-
esartan/Amlodipin/Hydrochlorthiazid) which resulted in a ‘no benefit’ conclusion
by the GBA. Companies claimed a proof in thirteen EBAs. IQWiG acknowledged a
proof in three EBAs. CONCLUSIONS: Both, evidence and benefit levels show major
differences between companies’ claims and IQWiG assessments. Most frequently
companies claimed a major benefit (11 EBAs) while IQWiG most frequently applied
the ‘no benefit’ category (8 EBAs).
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OBJECTIVES: Screening technologies are on the forefront of innovation and have
an impact on the care of patients in terms of identifying disease and appropriate
treatment options at an early stage. As such, screening technologies are of key
interest to health technology assessment (HTA) agencies in the United States (US)
and abroad. The objective of this research study is to evaluate existing technology
assessment standards for screening technologies in order to establish a best prac-
tice that may be implemented by US technology assessment organizations to
broaden the criteria used in assessments for screening products. METHODS: Qual-
itative interviews involving 12 HTA experts from the US, Canada, and the UK were
conducted. The experts represented HTA organizations that were for profit, not for
profit, government agencies, private payers, and academic medical centers. While
quantitative analysis of the levels of evidence required by HTA organizations for
screening products would produce a desirable study design, the findings from the
literature review indicated that quantitative evidence does not exist.RESULTS:The
results of this study indicate that the best practices should include criteria to sup-
port screening reliability, sensitivity and specificity; evaluate data to identify ap-
propriate patient populations; reference to the natural course of the disease; con-
sider ethical implications; and the impact of cost. CONCLUSIONS: HTA criteria
specific to the evaluation of screening products would positively impact HTA stake-
holders such as HTA organizations, their clients, patients, as well as technology
innovators. Best practices designed to help HTA organizations choose criteria that
are focused on screening technologies will help to identify whether relevant pa-
tient populations for the technology exist. In so doing, levels of evidence and data
requirements would be more transparent to screening technology innovators and
patients. Cost should be a part of the assessment to understand the cost and benefit
of using the product in specific patient populations for appropriate clinical decision
making.
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OBJECTIVES: Estimating the critical threshold value from previous reimbursement
decisions is one of the several methods to determine a cost effectiveness threshold.
The methodology is based on analyzing the relationship between the Incremental
Cost Effectiveness Ratio (ICER) of the assessed health technologies, and the reim-
bursement decisions. Our study tries to examine if there is any relationship be-
tween cost effectiveness and decision making in Hungary by analyzing data ab-
stracted from HTA appraisals and health economic studies. METHODS: The
members of the HTA Department examined the submissions containing a cost-
utility analysis which were assessed by the Hungarian HTA Office since 2004. We
created a database in which we summed up the cost/QALY values of the examined
submissions and HTA reports. We analyzed the appraisal determinations of the
HTA Committee regarding the assessed submissions in order to examine the like-
lihood of a positive/negative decision according the level of the assessed pharma-
ceutical’s ICER value. We searched for the technology with the highest ICER value,
which got reimbursed. RESULTS: We examined 165 submissions which contained
a cost-utility analysis that have arrived to our Department. Our results suggest that
there is only a weak correlation (r0,14) between the level of the calculated ICER
and the reimbursement decisions. We found, that the highest ICER which resulted
a positive reimbursement decision was 9 500 000 HUF/QALY (32 000 EUR).
CONCLUSIONS: One of the several methods to determine a threshold value is to
examine the relationship between previous reimbursement decisions and ICER
values calculated in health economic appraisals. However one must take into ac-
count, that estimating a threshold value based on prior decisions has limitations,
as reimbursement decisions are almost never made based on ICER ratios alone.
This could be the main reason our study only showed a weak correlation between
the level of calculated ICERs and the outcomes of the determinations.
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OBJECTIVES: To identify, using HTAinSite, if and how manufacturers have used
improved patient compliance as a value argument for their product in submissions
to the National Institute for Health and Clinical Excellence (NICE). We analysed if
and how compliance data were presented, how they were received by NICE, and if
they were an influential factor in NICE’s decision making.METHODS: A key phrase
search in HTAinSite was used to identify instances of ‘compliance’ and ‘adherence’
in manufacturer submissions and NICE technology appraisal (TA) documents. Af-
ter review for relevance, information was extracted and used to conduct a qualita-
tive analysis. RESULTS: Fifteen manufacturer’s submissions and 12 TAs reported
an improvement in compliance as a value argument for their drug. Factors used to
justify improved compliance included improved convenience, a reduction in ad-
verse events, increased treatment choice, and improved route of administration. In
8 of 13 TAs (relating to 11 manufacturer submissions), NICE state that the compli-
ance argument was considered by the Committee. In the remaining 5 TAs, despite
inclusion of a compliance argument by manufacturers in their submissions, the
Committee made no reference to it in the TA. Interestingly, only three manufac-
turers explicitly reported evidence supporting their compliance argument; how-
ever, the Committee discussed this in all of the associated TAs. The impact of
improved compliance on clinical outcomes or cost-effectiveness was frequently
not clearly reported by manufacturers or NICE. NICE did not explicitly cite compli-
ance as an influential factor in their final decision in any TAs. CONCLUSIONS: The
committee are more likely to consider a compliance argument if there is a clear
clinical rationale and it is accompanied by supporting data. Although compliance
arguments are considered by the Committee, NICE have not explicitly stated to
have used them to influence final decisions.
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OBJECTIVES: In 2011 was introduced the early benefit assessment with the new
pharmaceutical restructuring act (AMNOG) in Germany. Only new launched phar-
maceuticals were assessed since this date. At the beginning of June were the first
calls by FJC of drugs which made available for the market before 2011. The objection
is to show relevant criteria for calling a launched product and to analyze which
issues and consequences are possible in the AMNOG process. METHODS: In the
first step was described the political situation before and after the AMNOG and the
potential criteria for a call of launched drugs prior the law. Afterwards it was shown
the dossier development and assessment, hearing, G-BA decision and price nego-
tiation. There were demonstrated possible issues and differences between assess-
ments of new and launched products in this procedure. RESULTS: There is only a
small time frame for dossier development and assessment. Manufacturers and
concerned institutions have to plan and prepare in early expected time. Pharma-
ceuticals mostly admitted for more than one indication, why there could be a high
number of clinical trials available. The assessment of prior 2011 launched drugs is
very difficult, because there was a retrospective change of frame conditions. The
main criteria for a call are the market volume and revenues, remaining patent
protection and the expected assessments of competitors, triggered by admission of
new drugs in next time. CONCLUSIONS: In the next years can be expected, that
G-BA will be assess more pharmaceuticals from indications that have a great in-
fluence for costs in German health care. The methods and criteria have to be
discussed with all involved parties.
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OBJECTIVES:Health plans and other decision making bodies regularly request that
pharmaceutical and biotechnology companies provide a standardized dossier con-
taining detailed information - not only on the drug’s safety and efficacy, but also on
its overall clinical, economic, and humanistic value relative to alternative thera-
pies. Independent focus groups and multi-country surveys identified several chal-
lenges related to convenient, real-time collaboration to access information and
tools developed by the pharmaceutical and biotechnology industry METHODS: In
the US, the Academy of Managed Care Pharmacy (AMCP) partnered with Dy-
maxium Healthcare Innovations to launch an electronic platform to meet imme-
diate needs of US (Health Care Decision Makers (HCDMs). The platform would
incorporate all the key components of decision making processes, and was de-
signed with leading HCDMs. A survey was also fielded to over 50 US decision mak-
ers and payers from 13 other countries to provide their feedback and input into
their local HTA needs. Local country HTA guidelines and formats (i.e AMCP format
in the US) from over 30 countries was incorporated into the overall design of the
platform. RESULTS: The US HCDM survey results indicated the following chal-
lenges: a) Difficulty navigating through large volumes of information (300 pages)
to use for internal reviews, b) Risks associated with review of information that is
out-dated due to the release of newly published safety and effectiveness informa-
tion, c) Lack of user-friendly, transparent models and tools that can be customized
to reflect a plan’s own population patterns. The international survey revealed sim-
ilar challenges and unmet needs by HCDMs that were similar to their US counter-
parts. This feedback is being incorporated into the development of international
versions of the eDossier system. CONCLUSIONS: Leading experts from regional
countries validated the unique needs of each region in conducting HTA reviews
and the various benefits an electronic platform such as the AMCP eDossier may
provide.
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OBJECTIVES: The patient perspective is considered critical for policy decision mak-
ers. However it is unclear how this perspective is incorporated within different HTA
processes. The research identified and compared how selected European HTA
agencies incorporate the patient view in the decision making process for drugs.
METHODS:We identified websites of six relevant European bodies: England (NICE),
France (HAS), Germany (IQWIG and GBA), Scotland (SMC) and Sweden (TLV). We
searched for: how PAG representatives are selected, how they provide input &
contribute to the decision making process and how they are supported by HTA.
Findings were transferred to Excel spreadsheet and sent to respective agencies for
validation. Five of the six HTA responded. RESULTS: No weighting exists on how
Patient Advocacy Group (PAG) input is measured with respect to other data sub-
missions, important differences were observed in the engagement of PAGs as part
of the HTA assessment. HAS appears to have little or no process for PAG involve-
ment in HTA. NICE, SMC and GBA provide a support unit to facilitate PAG input. The
selection process of PAG for involvement in the process is well defined for G-BA,
TLV, NICE and SMC though TLV uses PAGs not related to the disease area under
review. G-BA & IQWIG involve individual patients, PAGs & consumer groups. Com-
prehensive PAG input to the process is publicly available for NICE and SMC. Only
TLV offers an equal voting right for PAGs. CONCLUSIONS: The patient perspective
is a significant contributor in the HTA decision making process. Although all HTA
agencies rely on patient information, significant differences exist in methods of
selection, input, impact and effort to support PAG input. Although such differences
are likely linked to cultural differences there is a need to improve and standardize
PAG input and integration in HTA decision making.
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OBJECTIVES: Personalized medicine is the use of diagnostic testing, including ge-
netic testing, to refine patient selection for the use of high cost procedures, devices,
and medicines. This study compares the processes for making coverage decisions
on multiple technologies between UK and Australia. METHODS: Comparative
study of assessments published by UK’s National Institute for Health and Clinical
Excellence (NICE) and Australia’s Commonwealth Department of Health.RESULTS:
The coverage of medical procedures, devices, and pharmaceuticals has been as-
sessed separately by different committees using conventional approaches of eco-
nomic evaluation in both UK and Australia. In 2005, NICE introduced a process to
assess multiple technologies (medicines, devices, medical procedures), such as
several drugs for the same condition, or one drug for several conditions. By con-
trast, Australia recently introduced an integrated assessment specifically for mul-
tiple, co-dependent technologies (‘personalized medicine’ products), such as med-
icines and their companion diagnostic tests. Health technologies are co-dependent
if their use needs to be combined to achieve or enhance the intended clinical effect
of either technology (e.g. gefitinib for patients with tested positive for an activating
mutation of the epidermal growth factor receptor gene in tumor). The co-depen-
dent technology assessment process was established in response to concerns that
1) only one technology in the co-dependent is reimbursed (e.g. a medicine is cov-
ered by the drug formulary while the companion test to determine responders is
not covered by Medicare), and 2) the assessment of a co-dependent technology
should consider the benefits and costs of their joint use, as distinct to the benefits
and costs of each technology alone. Analysis is underway to compare the timeli-
ness and recommendationsfor personalized medicine products between UK and
Australia. CONCLUSIONS: Important lessons are to be learned from the existing
experiences as health technologies are increasingly used either sequentially or
simultaneously in the continued development of personalized medicine.
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OBJECTIVES: The AMNOG has been in place for new drugs in Germany since 01/
01/2011. The AMNOG includes early benefit assessment in comparison to one pre-
defined ‘appropriate comparator’ therapy and negotiation of reimbursement price.
The objective of this research was to review and compare the outcomes of all
benefit assessments which had had in place a final decision until June 2012.
METHODS: A review based on all published documents of the AMNOG processes
(benefit dossiers submitted, IQWiG assessment reports and final G-BA decisions).
This investigation focuses on the comprehensive description and comparison of
outcomes of assessment and final decision. RESULTS: Until June 10, 2012, a total of
n14 AMNOG processes were finalized. For further 4 processes no dossier was
submitted. An additional benefit was partially credited 7 (50 %) out of the 14 new
drugs by the IQWiG and 10 (71%) by the G-BA. The IQWiG differentiated 39 sub-
populations for separate assessment and the G-BA considered 31 subpopulations
in the final decisions. The IQWiG credited 26 out of 39 subpopulations (67 %) with
‘no proof of additional benefit’. A total of 3 (8 %) subpopulations was credited with
‘significant’ additional benefit, 2 (5%) with ‘marginal’, and 6 (16 %) with ‘additional
benefit not quantifiable’. The G-BA finally credited 18 out of 31 subpopulations
(58%) with ‘no proof of additional benefit’ or ‘less benefit’. A total of 2 (6%) subpopu-
lations were credited with ‘significant additional benefit’, 5 (16%) with ‘marginal
additional benefit’, and 6 (20%) with ‘additional benefit not quantifiable’.
CONCLUSIONS: The AMNOG evaluation of additional benefit differentiates a high
number of subpopulations. Obviously the number of subpopulations and the out-
comes varied between IQWiG assessment and final G-BA decision. So far, the ma-
jority of subpopulations were credited with ‘no proof of additional benefit’. First
results from reimbursement negotiations suggest that this may restrict price
agreement.
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OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. The Institute for Quality and Efficiency in Health
Care (IQWiG) assesses the benefit of a drug based on a dossier submitted by the
pharmaceutical manufacturer. Based on this assessment and the statements by
industry, scientific community and patient organizations the Federal Joint Com-
mittee (FJC) reviews and decides on the extent of the additional benefit being the
basis for price negotiations between the National Association of Statutory Health
Insurance Funds and the pharmaceutical manufacturer. The objective is to inves-
tigate possible differences between the scientific assessments by IQWiG and the
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